TKD Stock Overview
Engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Takeda Pharmaceutical Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥25.59 |
| 52 Week High | JP¥27.80 |
| 52 Week Low | JP¥23.54 |
| Beta | 0.46 |
| 11 Month Change | 0.27% |
| 3 Month Change | -5.05% |
| 1 Year Change | -0.54% |
| 33 Year Change | 3.98% |
| 5 Year Change | n/a |
| Change since IPO | -10.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| TKD | AT Pharmaceuticals | AT Market | |
|---|---|---|---|
| 7D | -0.8% | 3.0% | -0.3% |
| 1Y | -0.5% | 5.7% | 2.5% |
Return vs Industry: TKD underperformed the Austrian Pharmaceuticals industry which returned 3.2% over the past year.
Return vs Market: TKD underperformed the Austrian Market which returned 2.3% over the past year.
Price Volatility
| TKD volatility | |
|---|---|
| TKD Average Weekly Movement | 2.0% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in AT Market | 6.5% |
| 10% least volatile stocks in AT Market | 1.8% |
Stable Share Price: TKD has not had significant price volatility in the past 3 months compared to the Austrian market.
Volatility Over Time: TKD's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1781 | 49,281 | Christophe Weber | www.takeda.com |
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands.
Takeda Pharmaceutical Company Limited Fundamentals Summary
| TKD fundamental statistics | |
|---|---|
| Market cap | €40.44b |
| Earnings (TTM) | €1.80b |
| Revenue (TTM) | €28.19b |
22.5x
P/E Ratio1.4x
P/S RatioIs TKD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TKD income statement (TTM) | |
|---|---|
| Revenue | JP¥4.55t |
| Cost of Revenue | JP¥1.55t |
| Gross Profit | JP¥3.00t |
| Other Expenses | JP¥2.71t |
| Earnings | JP¥290.00b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 182.94 |
| Gross Margin | 65.95% |
| Net Profit Margin | 6.38% |
| Debt/Equity Ratio | 73.0% |
How did TKD perform over the long term?
See historical performance and comparisonDividends
4.8%
Current Dividend Yield104%
Payout RatioDoes TKD pay a reliable dividends?
See TKD dividend history and benchmarks| Takeda Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Sep 27 2024 |
| Dividend Pay Date | Dec 02 2024 |
| Days until Ex dividend | 58 days |
| Days until Dividend pay date | 8 days |
Does TKD pay a reliable dividends?
See TKD dividend history and benchmarks